Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caris Life SciencesCAI -3.16%12 EV-to-OCF is 38.27 as of Sep. 10, 2026, which is 44% above its 10-year median of 26.49. GuruFocus rates CAI with a GF Score™ of 12/100. The stock has 6 warning signs investors should review. Among 1,404 Biotechnology companies, Caris Life Sciences ranks worse than 93.87% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Caris Life Sciences's Enterprise Value is $6,450.1 Mil.
Caris Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $168.6 Mil. Therefore, Caris Life Sciences's EV-to-OCF for today is 38.27.
The historical rank and industry rank for Caris Life Sciences's EV-to-OCF or its related term are showing as below:
CAI'
s EV-to-OCF Range Over the Past 10 Years
Min: -16697.15 Med: 26.49 Max: 92.4
Current: 38.27
During the past 4 years, the highest EV-to-OCF of Caris Life Sciences was 92.40. The lowest was -16697.15. And the median was 26.49.
CAI's EV-to-OCF is ranked worse than 93.87% of 1404
companies
in the Biotechnology industry
Industry Median: -3.65
vs CAI: 38.27
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Caris Life Sciences (NAS:CAI) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Caris Life Sciences's PE Ratio (TTM) for today is calculated as:
Caris Life Sciences's share price for today is $24.03.
Caris Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.360.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Caris Life Sciences EV-to-OCF Related Terms
Caris Life Sciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Caris Life Sciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Caris Life Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caris Life Sciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caris Life Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Caris Life Sciences's EV-to-OCF falls into.
Caris Life Sciences's current Enterprise Value is $6,450.1 Mil.
Caris Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $168.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caris Life Sciences (CAI) has a EV-to-OCF of 38.27 as of Sep. 10, 2026. This is 44% above median its historical median of 26.49. According to the industry distribution chart, Caris Life Sciences ranks #1318 out of 1404 companies in the Biotechnology industry, placing it in the top 93.9%.
Is Caris Life Sciences' EV-to-OCF too high?
Caris Life Sciences' current EV-to-OCF of 38.27 is 44% above median its 10-year median of 26.49. Based on the distribution chart, Caris Life Sciences ranks #1318 out of 1404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caris Life Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' EV-to-OCF compare to RYTM and SRRK?
According to the Biotechnology industry distribution chart, Caris Life Sciences ranks #1318 out of 1404 companies for EV-to-OCF. This places Caris Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Caris Life Sciences's current EV-to-OCF is 38.27, which is 44% above median its own 10-year median of 26.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (CAI) has a current EV-to-OCF of 38.27. The current EV-to-OCF is 38.27, which is 44% above median its 10-year median of 26.49. Caris Life Sciences' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Caris Life Sciences (CAI), the current EV-to-OCF is 38.27 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
12GF Score
Get the complete analysis for CAI
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI has been successfully added to your 
